Compare Ascendis Pharma A/S (ASND) vs Chubb Ltd (CB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Chubb Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Chubb Ltd trades at $350.16 (market cap $134.91B). The key difference: Chubb Ltd is far larger — about 7.6× Ascendis Pharma A/S's market cap, and Chubb Ltd pays a 1.17% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CB | |
|---|---|---|
Market Cap | $17.74B | $134.91B |
Sector | Health | Financials |
52-Week High | $277.18 | $361.17 |
52-Week Low | $163.32 | $265.99 |
Enterprise Value | $18.11B | $155.96B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Chubb Limited (CB) trades at $347.83, showing minimal daily movement with a slight 0.01% gain. The stock exhibits bullish technical signals from moving averages and strong fundamental health, including consistent earnings beats and a net income margin of 18.46%. Recent news highlights disciplined capital deployment and premium growth, while the upcoming Q2 2026 earnings report on July 22, 2026, is highly anticipated.
The outlook remains positive given analyst consensus favoring Buy ratings and a price target of $354.69, suggesting modest upside. Key risks include catastrophe losses and softer commercial pricing, but the company's robust balance sheet and rising investment income support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
